Preclinical data generated in cynomolgus monkeys have shown no off-target side effects, no evidence of CRS, and no dermatologic toxicities characteristic to EGFR signaling inhibitors (TKIs and anti-EGFR antibodies) (241). Here, EGFR is linked to congenital rubella syndrome.